Related references
Note: Only part of the references are listed.Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model
Razieh Kebriaei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study
T. Huwyler et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Beyond Vancomycin: The Tail of the Lipoglycopeptides
Kenneth P. Klinker et al.
CLINICAL THERAPEUTICS (2015)
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review
Francoise Van Bambeke
DRUGS (2015)
Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
J. S. Davis et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
High-Dose Continuous Oxacillin Infusion Results in Achievement of Pharmacokinetics Targets in Critically Ill Patients with Deep Sternal Wound Infections following Cardiac Surgery
Nicolas Nesseler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections
Stuart L. Burke et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter
S. J. van Hal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin
Michael T. Guskey et al.
PHARMACOTHERAPY (2010)
Telavancin: A Novel Lipoglycopeptide Antibiotic
Lisa Charneski et al.
ANNALS OF PHARMACOTHERAPY (2009)
Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis
Shuli Svetitsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity
Thomas P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Telavancin: An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections
Steven N. Leonard et al.
PHARMACOTHERAPY (2008)
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S-aureus (MRSA) blood isolates from 2001-05
Gregory Steinkraus et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Dalbavancin: a novel antimicrobial
A. Y. Chen et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
SM Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo
RO Darouiche et al.
JOURNAL OF INFECTION (2005)
Mechanism of action of oritavancin and related glycopeptide antibiotics
NE Allen et al.
FEMS MICROBIOLOGY REVIEWS (2003)
Share Paper
